Chemed Co. (NYSE:CHE – Get Free Report) CFO David Patrick Williams sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $580.79, for a total value of $2,903,950.00. Following the sale, the chief financial officer now directly owns 10,826 shares in the company, valued at $6,287,632.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
David Patrick Williams also recently made the following trade(s):
- On Tuesday, November 7th, David Patrick Williams sold 6,000 shares of Chemed stock. The stock was sold at an average price of $583.85, for a total value of $3,503,100.00.
Chemed Trading Up 0.1 %
Shares of CHE opened at $582.72 on Tuesday. Chemed Co. has a 12 month low of $481.99 and a 12 month high of $590.58. The stock’s 50 day moving average is $527.51 and its two-hundred day moving average is $531.50. The firm has a market cap of $8.78 billion, a P/E ratio of 36.08, a PEG ratio of 3.39 and a beta of 0.49.
Chemed Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be paid a dividend of $0.40 per share. The ex-dividend date is Friday, November 10th. This represents a $1.60 annualized dividend and a yield of 0.27%. Chemed’s dividend payout ratio (DPR) is 9.91%.
Institutional Investors Weigh In On Chemed
A number of institutional investors have recently modified their holdings of CHE. Rice Hall James & Associates LLC acquired a new stake in shares of Chemed in the first quarter valued at $273,000. Raymond James Financial Services Advisors Inc. grew its stake in shares of Chemed by 13.3% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 1,957 shares of the company’s stock valued at $992,000 after buying an additional 230 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Chemed by 7.2% in the first quarter. American Century Companies Inc. now owns 2,018 shares of the company’s stock valued at $1,022,000 after buying an additional 135 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of Chemed by 6.2% in the first quarter. HighTower Advisors LLC now owns 836 shares of the company’s stock valued at $432,000 after buying an additional 49 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its stake in shares of Chemed by 495.0% in the first quarter. Panagora Asset Management Inc. now owns 2,261 shares of the company’s stock valued at $1,145,000 after buying an additional 1,881 shares in the last quarter. 94.25% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research firms recently commented on CHE. StockNews.com began coverage on Chemed in a report on Thursday, October 5th. They set a “buy” rating on the stock. Royal Bank of Canada raised their target price on Chemed from $576.00 to $604.00 and gave the stock an “outperform” rating in a report on Monday, October 30th.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
- Five stocks we like better than Chemed
- What Are Dividends? Buy the Best Dividend Stocks
- Catch the dip on Sociedad Quimica before earnings?
- When to Sell a Stock for Profit or Loss
- Can new GPT store spur generative AI monetization?
- What is a SEC Filing?
- Energy looks to dominate markets with 3 oil and gas stocks
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.